Gilead Sciences Inc. dropped dosing of its non-nucleoside polymerase inhibitor GS 9190 in combination with interferon and ribavirin in the wake of two adverse events in separate studies testing four-drug regimens in patients with hepatitis C virus (HCV), but the news is not expected to affect the firm's all-oral, interferon-free HCV program.